Fenwick & West LLP represented investors Kleiner Perkins Caufield & Byers and Texas Pacific Group in their recently announced investment in BioCryst Pharmaceuticals (NASDAQ: BCRX). BioCryst Pharmaceuticals designs, optimizes and develops small molecule pharmaceuticals that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The financing is intended to provide BioCryst with the resources it needs to pursue broad clinical trials of peramivir, an antiviral agent designed to treat seasonal and pandemic strains of influenza. The $30.0 million registered direct offering of 2,228,829 shares of BioCryst common stock was priced at $13.46 per share, pursuant to BioCryst's shelf registration statements that were declared effective by the Securities and Exchange Commission on January 5, 2004 and September 20, 2005.
More information about the transaction can be obtained from the BioCryst Web site.
The Fenwick & West transaction team consisted of corporate attorneys Gordon Davidson, Jeffrey Vetter, Sayre Stevick, Sergio Garcia, Kris Withrow and Intellectual Property attorneys Michael Shuster and Narinder Banait.
About Fenwick & West
Fenwick & West provides comprehensive legal services to high technology and life sciences clients of national and international prominence. The firm was ranked by MergerMarket as the #1 U.S. Legal Advisor for Technology Industry M&A in 2004.